Avenue Therapeutics, Inc. (ATXI)

6.20 -2.58 (-29.35%) At close: 04:00PM EDT

Avenue Therapeutics, Inc.

1111 Kane Concourse
Suite 301
Bay Harbor Islands, FL 33154
United States
781 652 4500
https://www.avenuetx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 3

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Alexandra MacLean M.D.	CEO & Director	413.2k	N/A	1968
Mr. David Jin	Interim CFO, COO & Corporate Secretary	N/A	N/A	1991
Dr. Lindsay Allan Rosenwald	Executive Director	N/A	N/A	1955
Dr. Xiaoqin Lu M.D.	Consultant	1.05M	N/A	1975
Dr. Scott A. Reines M.D., Ph.D.	Interim Chief Medical Officer	69.12k	N/A	1947
Mr. Srinivas Subramanian	Executive Vice President	N/A	N/A	1971

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Corporate Governance

Avenue Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.